Market Place
Sourcing Support
European Commission Approves ORKAMBI for Cystic Fibrosis
05 Jul 2023 //
BUSINESSWIRE
Vertex Announces Health Canada Market Authorization for ORKAMBI& in Children
11 Apr 2023 //
BIOSPACE
Vertex (VRTX) CF Drug Gets FDA Expanded Label for Toddlers Nasdaq
05 Sep 2022 //
NASDAQ
Vertex Announces U.S. FDA Approval for ORKAMBI in Children
03 Sep 2022 //
BUSINESSWIRE
ICER Issues Report& Policy Recommendations on Treatments for Cystic Fibrosis
23 Sep 2020 //
PRESS RELEASE
Switzerland reaches reimbursement deal for Vertex CF drugs
22 Apr 2020 //
PRESS RELEASE
Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI®
20 Apr 2020 //
BUSINESSWIRE
Vertex deal with Wales expands cystic fibrosis treatment coverage to all of UK
14 Nov 2019 //
REUTERS
Vertex`s cystic fibrosis portfolio to be made available across Northern
13 Nov 2019 //
PHARMAFILE
Spanish Government Approves National Reimbursement of ORKAMBI®
21 Oct 2019 //
BUSINESSWIRE
Labour Party takes aim at pharma, calls attention to Orkambi row
26 Sep 2019 //
PMLIVE
U.K.Labour Party wants government to build its own manufacturing
25 Sep 2019 //
FIERCE PHARMA
Vertex faces rejection of its CF medicines in Scotland
14 Aug 2019 //
PMLIVE
Vertex touts Symdeko success after CEO turnover, Orkambi stumble
31 Jul 2019 //
FIERCE PHARMA
Orkambi row: government now considering Crown Use licensing
12 Jun 2019 //
PMLIVE
Orkambi debate in U.K. revives the myth of a people-funded drug
11 Jun 2019 //
FIERCE BIOTECH
Vertex makes choice for all-important CF triple therapy
01 Jun 2019 //
PMLIVE
Still no breakthrough on Orkambi talks, MPs want answers
22 May 2019 //
PMLIVE
CF advocates ratchet up pressure on Vertex, NHS officials
09 Apr 2019 //
FIERCE PHARMA
Vertex destroys 8,000 Orkambi packs amid U.K. pricing standoff
29 Mar 2019 //
FIERCE PHARMA
Vertex CEO to sit down with Britain`s health chief on Orkambi
09 Mar 2019 //
FIERCE PHARMA
Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough
07 Mar 2019 //
PMLIVE
How to fix a problem like Orkambi? Solutions suggested ahead of showdown
05 Mar 2019 //
PMLIVE
Vertex CEO, CCO head for U.K. hearing on Orkambi pricing standoff
05 Mar 2019 //
FIERCE PHARMA
Outrage as cystic fibrosis drug firm posts big profit
11 Feb 2019 //
THE GUARDIAN
MPs threaten to hijack Vertex’s IP for its cystic fibrosis drugs
01 Feb 2019 //
ENDPTS
Vertex to submit Orkambi, Symkevi to SMC
20 Dec 2018 //
PHARMA TIMES
Catalyst will charge $375,000 for rare disease drug
13 Dec 2018 //
STAT NEWS
MPs order release of documents on negotiations for Vertex’ CF drugs
12 Nov 2018 //
PHARMA TIMES
Vertex CEO- competitive edge is honed and ready for AbbVie`s CF grab
26 Oct 2018 //
FIERCE PHARMA
Vertex Announces Access Contract in Denmark for Current and Future CF Medicines
01 Oct 2018 //
PRESS RELEASE
Pharma`s slow embrace of continuous manufacturing
26 Sep 2018 //
BIOPHARMA DIVE
Vertex Completes Enrollment of 2 PhIII Studies on VX-659+Tezacaftor+ Ivacaftor
06 Sep 2018 //
BUSINESSWIRE
Vertex Finalizes Orkambi Deal With Australia
04 Sep 2018 //
BIOCENTURY
Vertex Announces Reimbursement Agreement in Australia for lumacaftor/ivacaftor
31 Aug 2018 //
BUSINESSWIRE
Vertex’s Orkambi CF drug okayed for funding in Australia
20 Aug 2018 //
PHARMAPHORUM
Vertex Receives +ve PBAC Recomm of ORKAMBI® (lumacaftor/ivacaftor)
19 Aug 2018 //
BUSINESSWIRE
Vertex: NHS England will have to do better with CF drugs offer
17 Jul 2018 //
FIERCE PHARMA
NHS does not value CF patients, says Vertex CEO in letter to PM
11 Jul 2018 //
PHARMA PHORUM
Vertex CEO to UK PM: You’re threatening the country’s biotech industry
10 Jul 2018 //
ENDPTS
Patients wait as Vertex, U.K. officials argue over Orkambi price
09 Jul 2018 //
FIERCE PHARMA
Vertex calls NHS England ‘outrageous’ as Orkambi talks stall again
05 Jul 2018 //
PM LIVE
Charity criticises NHSE and Vertex over Orkambi access, Sema scores, NodThera
25 Jun 2018 //
PMLIVE
Vertex Announces Long-Term Access Agreement in Sweden for ORKAMBI®
18 Jun 2018 //
BUSINESSWIRE
Proteostasis Announces +ve Data from Ongoing Ph1 Study of PTI-801 in CF Orkambi®
07 Jun 2018 //
PR NEWSWIRE
Proteostasis Announces +ve Data from Ongoing Ph1 Study of PTI-801 in CF Pts
06 Jun 2018 //
PR NEWSWIRE
Enforcement Report - Week of May 16, 2018
16 May 2018 //
FDA
Ministers write letter to Vertex over Orkambi debate
23 Apr 2018 //
PHARMA TIMES
Vertex offers ‘portfolio approach’ to secure access to CF meds
19 Feb 2018 //
PHARMA TIMES
Vertex`s two-drug cystic fibrosis treatment cleared in US
14 Feb 2018 //
PMLIVE
Vertex execs whip up a cheer from the analysts after hedging their bet
02 Feb 2018 //
ENDPTS
Vertex’s Orkambi receives EU green light for licence extension
11 Jan 2018 //
PMLIVE
Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor)
10 Jan 2018 //
BUSINESSWIRE
Vertex’ CF therapy Orkambi cleared for younger patients
10 Jan 2018 //
PHARMA TIMES
Vertex strikes Italian reimbursement deal for Orkambi
13 Jul 2017 //
PMLIVE
Irish Health Service Cover Vertex’s Cystic Fibrosis Therapies Orkambi & Kalydeco
05 Jun 2017 //
LUNG DISEASES NEWS
Vertex` Orkambi (Lumacaftor/Ivacaftor) Approved in US For Cystic Fibrosis
05 Jul 2015 //
FDA
Vertex beefs up its cystic fibrosis pipeline with $1.2B Parion R&D pact
05 Jun 2015 //
FIERCE BIOTECH
Late-stage data back Orkambi benefit in cystic fibrosis
17 May 2015 //
PHARMA TIMES
